Plymouth Lane Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Plymouth Lane Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-50,989	Closed	-$1.01M	–	29
2015 Q3	$1.01M	Sell	50,989 -49,061	-49%	-$1.55M	0.52%	20
2015 Q2	$3.48M	Buy	+100,050	New	+$3.05M	1.73%	10

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Plymouth Lane Capital Management's HZNP Position: Q4 2015 in Review

Plymouth Lane Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 50,989 shares — an estimated $1.01M sold.

Plymouth Lane Capital Management first reported a position in HZNP in Q2 2015 and held it in 2 quarters. The position peaked at $3.48M in Q2 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

Plymouth Lane Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
Plymouth Lane Capital Management sold 50,989 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $1.01M.
Plymouth Lane Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 2 quarters.
Plymouth Lane Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.48M in Q2 2015.
202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Plymouth Lane Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.